Spiliotis Bondy CA, Van PL, Bakalov VK, et al. 2006. Growth hormone treatment and aortic dimensions in Turner syndrome. J Clin Endocrinol Metab, 91:1785–8. Bondy CA; Turner Syndrome Consensus Study Group. 2007. Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab, 92:10–25. Carel JC, Mathivon L, Gendrel C, et al. 1997. Growth hormone therapy for Turner syndrome: evidence for beneﬁt. Horm Res, 48:31–4. Chernausek SD, Attie KM, Cara JF, et al. 2000. Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on ﬁnal height. Genentech, Inc. Collaborative Study Group. J Clin Endocrinol Metab, 85:2439–5. Davenport ML, Punyasavatsut N, Gunther D, et al. 1999. Turner syndrome: a pattern of early growth. Acta Pediatr Suppl, 88:118–21. Davenport ML, Crowe BJ, Travers SH, et al. 2007. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab, 92:3406–16. Fechner PY, Davenport ML, Qualy RL, et al. Toddler Turner Study Group. 2006. Differences in follicle-stimulating hormone secretion between 45, X monosomy Turner Syndrome and 45, X/46 XX mosaicism are evident at early age. J Clin Endocrinol Metab, 91:4896–902. Gravholt CH, Frystyk A, Flyvbjerg A, et al. 2001. Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids. Am J Physiol, 280: E308–E14. Gravholt CH, Chen JW, Oxvig C, et al. 2006. The GH-IGF-IGFBP axis is changed in Turner syndrome: partial normalization by HRT. Growth Hormone IGF Res, 16(5–6):332–9. Hamelin CE, Anglin G, Quigley CA, et al. 2006. Genomic imprinting in Turner syndrome: effects on response to growth hormone and on risk of sensorineural hearing loss. J Clin Endocrinol Metab, 91:3002–10. Haverkamp F, Wolﬂe J, Zerres K, et al. 1999. Growth retardation in Turner syndrome: aneuploidy, rather than speciﬁc gene loss, may explain growth failure. J Clin Endocrinol Metab, 84:4578–82. Ho KY, Evans WS, Blizzard RM, et al. 1987. Effects of sex and age on the 24-hour proﬁle of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab, 64:51–8. Hogler W, Briody J, Moore B, et al. 2004. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry. J Clin Endocrinol Metab, 89:193–9. Hofman P, Cutﬁels WS, Robinson EM, et al. 1997. Factors predictive of response to growth hormone therapy in Turner’s syndrome. J Pediatr Endocrinol Metab, 10:27–33. Lyon AJ, Preece MA, Grant DB. 1985. Growth curve for girls with Turner syndrome. Arch Dis Child, 60:932–5. Marchini A, Maritila T, Winter A, et al. 2004. The short stature home- odomain protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes. J Biol Chem, 279:37103–14. Massa GG, Vanderschueren-Lodeweyckx M, Malvaux P. 1990. Linear growth in patients with Turner syndrome: inﬂuence of spontaneous puberty and parental height. Eur J Pediatr, 149:246–50. Munns CJF, Haase HR, Crowther LM, et al. 2004. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab, 89:4130–5. Nielsen J, Wohlert M. 1991. Chromosome abnormalities found among 34,910 newborn-children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet, 87:81–3. Park P, Cohen P. 2004. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res, 62(Suppl 1):59–65. Piippo S, Lenko H, Kainulainen P, et al. 2004. Use of percutaneous estro- gen gel for induction of puberty in girls with Turner syndrome. J Clin Endocrinol Metab, 89:3241–7. Ogata T, Matsuo, N. 1993. Sex chromosome aberrations and stature:deduc- tion of the principal factors involved in the determination of adult height. Hum Genet, 91:551–62. 1182 Quigley CA, Crowe BJ, Anglin DG, et al. 2002. Growth hormone and low dose estrogen in Turner syndrome: Results of a United States multi- center trial to near-ﬁnal height. J Clin Endocrinol Metab, 87:2033–41. Radetti G, Crepaz R, Milanesi O, et al. 2001. Cardiac performance in Turner’s syndrome patients on growth hormone therapy. Horm Res, 55:240–4. Ranke MB, Lindberg A, Chatelain P, et al. 2000. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS Interna- tional Board. Kabi International Growth Study. J Clin Endocrinol Metab, 85:4212–8. Ranke MB, Lindberg A. 2007. Turner syndrome within KIGS including an analysis of 1146 patients grown to near adult height. In: Ranke MB, Price DA, Reiter EO (eds). Growth Hormone Therapy in Pediatrics – 20 years of KIGS. Basel: Karger. p 332–9. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordisiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA. 1997. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet, 16:54–63. Rao E, Blaschke RJ, Marchini A, et al. 2001. The Leri-Weill and Turner syndrome homeobox gene SHOX encodes a cell-type speciﬁc tran- scriptional activator. Hum Mol Genet, 10:3083–91. Reiter EO, Blethen SL, Baptista J, et al. 2001. Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner’s syndrome. J Clin Endocrinol Metab, 86:1936–41. Rongen-Westerlaken C, Corel L, van d, Broeck J, et al. 1997. Reference values for height, height velocity and weight in Turner’s syndrome. Swedish Study Group for GH treatment. Acta Paediatrica, 86:937–42. Rosenfeld RG, Hintz RL, Johanson AJ, et al. 1986. Methionyl human growth hormone and oxandrolone in Turner syndrome: preliminary results of a prospective randomized trial. J Pediatr, 109:936–43. Rosenfeld RG, Attie KM, Frane J, et al. 1998. Growth hormone therapy of Turner’s syndrome: Beneﬁcial effect on adult height. J Pediatr, 132:319–24. Rosenfeld RG, 2007. In: Growth Hormone Therapy in Pediatrics – 20 years of KIGS. Ranke MB, Price DA, Reiter EO (eds). Basel, Karger. p. 326–31. Rosenﬁeld RL, Perovic N, Devine N, et al. 1998. Optimizing estrogen replacement treatment in Turner syndrome. Pediatr, 102:486–8. Rosenﬁeld RL, Devine N, Hunold JJ, et al. 2005. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab, 90:6424–30. Ross JL, Cassorla FG, Skerda MC, et al. 1983. A preliminary study of the effect of estrogen dose on growth in Turner syndrome. N Engl J Med, 309:1104–6. Ross JL, Long LM, Loriaux DL, et al. 1985. Growth hormone secretory dynamics in Turner syndrome. J Pediatr, 106:202–6. Ross JL, Kowal K, Quigley CA, et al. 2005. The phenotype of short stature homeobox gene (SHOX) deﬁciency in childhood: contrasting children with Leri-Weill dyschondrosteosis and Turner syndrome. J Pediatr, 147:499–507. Ross JL, Quigley CA, Cao D, et al. 2007. Early low-dose estrogen increases adult height gain in GH-treated patients with Turner syndrome (TS): results of a double-blind, randomized placebo-controlled clinical trial. Pediatric Academic Societies’ Annual Meeting, Toronto, Canada, Abstract Number: 7515.5. Rovet J, Ireland L. 1994. Behavioral phenotype in children with Turner syndrome. J Ped Psychol, 19:779–90. Rovet J. 2004. Turner syndrome: a review of genetic and hormonal inﬂuences on neuropsychological functioning. Neurospychol Dev Cogn C Child Neurospychol, 10:262–79. Saenger P. 1996. Turner’s syndrome. N Engl J Med, 335:1749–54. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, et al. 1999a Normaliza- tion of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab, 84:4607–12. Therapeutics and Clinical Risk Management 2008:4(6)